STAT News

SEPTEMBER 26, 2022

— The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a bit of a misnomer. CAMBRIDGE, Mass.

Biohazard 140

Biohazard Biohazard Gene Genetics 140

Cloudbyz

APRIL 9, 2023

Here are some ways to bring sustainability into clinical trial management: Reduce waste: Clinical trials generate a significant amount of waste, including packaging materials, medical equipment, and biohazardous waste. For example, properly storing and disposing of biohazardous waste can prevent contamination of the environment.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Biohazard 52

Advarra

AUGUST 31, 2022

All potentially infectious sharps must be disposed of in a biohazard sharps container immediately after use without recapping. Once loaded and capped, the syringe must be transported to the clinic in a sealed, leak-proof, and biohazard-labeled container. Needles must not be bent or sheared. Safety-engineered Syringes. Recapping tools.

Biohazard 52

Biohazard Biohazard Production Genetics 52

Advarra

OCTOBER 26, 2023

And don’t forget to affix a biohazard sticker to the exterior for quick and clear identification. A secure latch is crucial to create a tight seal; it ensures the lid stays put and the contents remain safely inside, even if the container takes a tumble. Size matters. Choose a container appropriately sized for its contents.

Production 52

Production Biohazard Biohazard Genetic Engineering 52

Worldwide Clinical Trials

JUNE 15, 2022

These therapies can have mechanisms that could expose people to biological or biohazardous agents, so therapies must be closely monitored and contained during transport, storage, and administration. Institutional Biosafety Committees (IBC) assess the risk of gene therapies to public health or the environment.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Advarra

JUNE 12, 2023

IBCs, however, seek to protect study personnel, the community, and the environment from exposure to engineered genetic material and other biohazardous agents. IRBs are tasked with protecting research subject’s rights and welfare.

Gene Therapy 98

Gene Therapy Genetic Engineering Genetics Gene 98

Pharmaceutical Technology

DECEMBER 19, 2022

However, stopping nucleation and growth is challenging and often involves the use of biohazardous substances. The first is the so-called “bottom-up” approach, where API nanoparticles are generated through agglomeration or granulation of single molecules. Further scaling-up is delicate and laborious.

Bioavailability 130

Bioavailability Production Biohazard Biohazard 130